ICD G23.3ORPHA:102MSA

Multiple System Atrophy

Multiple System Atrophy is a rare and fatal neurodegenerative disease that affects movement, balance, and the autonomic nervous system. It is characterised by alpha-synuclein deposits in glial cells. MSA progresses faster than Parkinson's disease, with median survival of 6-10 years from symptom onset. Diagnosis is challenging and often delayed.

547
Articles
166
Trials (6 AU)
Updated
5 April 2026
Loading...

Common Questions

What is Multiple System Atrophy?

Multiple System Atrophy is a rare and fatal neurodegenerative disease that affects movement, balance, and the autonomic nervous system. It is characterised by alpha-synuclein deposits in glial cells. MSA progresses faster than Parkinson's disease, with median survival of 6-10 years from symptom onset. Diagnosis is challenging and often delayed.

How many clinical trials are available for Multiple System Atrophy?

RareWays currently indexes 166 clinical trials for Multiple System Atrophy, of which 55 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Multiple System Atrophy come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Multiple System Atrophy.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.